We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | 0.80 | 0.80 | 0.80 | 198,696 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 0 | -1.03M | -0.0057 | -1.40 | 1.45M |
Date | Subject | Author | Discuss |
---|---|---|---|
29/8/2018 07:18 | Hallelujah. At last he admitted I was correct......but in an obtuse way. Let's see now if there is a fund raising before Christmas.... Do you think hugh gives good advice with his myopic view of N4P? LOL! You couldn't make it up. Nobby | nobbygnome | |
28/8/2018 22:56 | technician??? Most of what I have written has been on my mobile these last few months which I absolutely hate doing as I am not the best typing with small keyboards, especially while in a rage. My absence is down to being very busy at the moment which means that I don`t have all day, every day like some here to argue with idiots. As for Nobbo, I would be very wary of asking the advice of someone with an agenda.Do you honestly believe that he is going to give you good advice? You could just wait for news from the company. Must admit to getting a little sick and tired of Nobbo`s I know all there is to know approach when he clearly doesn`t. His research on N4 has been pitiful at best. As for therapeutic over vaccine, therapeutics is an area for Nuvec to grow into, which if Nobbo had any knowledge of N4 he would know. For now, it is the vaccine approach that is being prioritized. | hughwilson | |
28/8/2018 09:32 | Yes he is!! | eddie_yates | |
28/8/2018 08:42 | What a plonker | onedayrodders | |
27/8/2018 13:01 | Mange tout mange tout Rodney, I’m not so sure about that!! Lots of folk on here have been hanging on every word of a man who can’t spell his alleged previous job title!! Or does he tell lies??? | eddie_yates | |
27/8/2018 12:08 | nobody cares either way | onedayrodders | |
27/8/2018 09:07 | LOL you shouldn't buy if you think there is going to be a fund raising. Having said that I am sure there will be some gerrymandered RNS to try to get the price up. Just IMHO of course..... | nobbygnome | |
27/8/2018 08:47 | Barrie 16, I wouldn't be asking Nobby the time of day. These shares are at their lowest and guess what you do when that happens:))) | ch1rp | |
26/8/2018 20:06 | Drug used in Viagra is linked to a record 19 UK deaths in a year as sale of the little blue pills skyrocket after it became legal to sell them without prescription... | someuwin | |
26/8/2018 20:00 | And I am not qualified to give investment advice. However, as I have said before I think the Viagra reformulation is at best a waste of time especially now it has been delayed and I expect a fund raising before Christmas. So I think you can extrapolate my view. All just IMHO.... Nobby | nobbygnome | |
26/8/2018 09:22 | Nobby I have a few shares in this company but am not qualified to doctorate level in pharmacy. In your opinion are the shares worth me, continuing to hold? | barrie16 | |
26/8/2018 07:18 | I went back and read Hugh's posts from January. So he is a lab technician who got made redundant from Pfizer. That apparently makes him an expert on Viagra.... If you read his posts from that period, the ramping was absolutely outrageous. I could post any number which would be embarrassing for him now. I recommend everyone should go and have a look to prove how completely wrong he has been. Hmmm so would you listen to a lab technician or a PhD. with 28 years experience in all aspects of drug development...... | nobbygnome | |
25/8/2018 22:18 | >> dplewis LOL was that his spelling too... | nobbygnome | |
25/8/2018 20:46 | The Nobby/Hugh show is entertaining and in fact has shown some great points which would have otherwise never been mentioned. I’ve personally topped up again and feel extremely comfortable with progression. Pharma is notoriously slow but when it strikes it shows in the share price spectacularly. Enjoy your long weekend guys. | featherby81 | |
25/8/2018 20:04 | hughwilson - 22 Jan 2018Parob.I was a lab technition.I think you're asking too much nobby / jimbo.. | dplewis1 | |
25/8/2018 19:07 | >> hugh This is your big chance to show I don't know what I am talking about....yet you fail to take it. The silence speaks volumes..... | nobbygnome | |
25/8/2018 17:45 | Hugh, no idea what nobby is in about. But I'd love to actually see you respond rather than just saying that things are obvious and investors already know. I bloody don't so feel free to explain | jimbobaroony | |
25/8/2018 17:38 | I thought school was closed at weekends :o/ | onedayrodders | |
25/8/2018 17:09 | LOL but no mention in the June announcement. Please explain.... You don't have a clue about the science do you. I suspect you don't know the difference between a therapeutic protein approach and a vaccine approach..... | nobbygnome | |
25/8/2018 16:55 | Nobbo, regarding the therapeutic proteins and the immune responses. If you had any knowledge of N4 or had done any research then you would already know the answer to that, so it's pretty clear that far from being the great know it all, you do in fact know very little. I bet most here could give you the answer to that, proper investors that is, not traders with little time for research. | hughwilson | |
25/8/2018 15:52 | >> hugh You still haven't explained why the therapeutic proteins approach is not in the June update about Nuvec. Is it happening or not? Or is it all about generating an immune response? Your followers would love to know.... | nobbygnome | |
25/8/2018 15:44 | Hugh, if they are derampers, that makes you a ramper | jimbobaroony |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions